TODD STRATEGY GROUP for CAREDX, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2026 | $60,000 | Replaced |
| 2nd Quarter - Termination | Oct 20, 2026 | $60,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE FLEMING COTTON | Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie |
| PAUL EDATTEL | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
| NICHOLAS UEHLECKE | Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.